Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharma... - PubMed - NCBI

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharma... - PubMed - NCBI

Therapie. 2017 Jan 30. pii: S0040-5957(17)30011-2. doi: 10.1016/j.therap.2016.09.018. [Epub ahead of print]

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.

Quaranta S1, Dupouey J2, Colle R3, Verstuyft C4.

Author information

Abstract

Tailoring antidepressant drug therapy to each individual patient is a complex process because these drugs have adverse effects leading to discontinuation. Pharmacogenetics may provide useful information in routine practice for optimizing antidepressant treatment by helping limit toxic effects while maintaining efficacy. This review presents the usefulness of pharmacogenetic tests for P450 cytochromes CYP2C19 and CYP2D6 in psychiatric patients taking antidepressants. Depending on the level of evidence, the French National Network of Pharmacogenetics (RNPGx) has issued recommendations stating that pharmacogenetic tests for CYP2D6 and CYP2C19 genes are potentially useful in psychiatric patients treated with antidepressant drugs.

Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

KEYWORDS:

Antidepressant drugs; CYP2C19; CYP2D6; Pharmacogenetics; Psychiatry

PMID:

 

28237405

 

DOI:

 

10.1016/j.therap.2016.09.018

[PubMed - as supplied by publisher]